Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

  • STATUS
    Recruiting
  • End date
    Nov 17, 2023
  • participants needed
    18
  • sponsor
    Catherine Bollard
Updated on 7 October 2022
lymphoma
hodgkin's disease
granulocyte colony stimulating factor
prednisone
measurable disease
colony stimulating factor
nivolumab
pulse oximetry
diffuse large b-cell lymphoma
b-cell lymphoma
pet/ct scan
salvage therapy
brentuximab
pd-1 inhibitor
refractory hodgkin lymphoma

Summary

This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in relapsed/refractory lymphoma (rel/ref) patients with measurable disease (group A) or as adjunctive therapy following autologous hematopoeitic stem cell transplant(HSCT) for patients at high risk of relapse (group B).

The purpose of this study is to find out if the tumor specific T cells given with Nivolumab are safe and to learn what the side effects are and if the combination can help patients with relapsed lymphomas.

Description

This Phase I, open-label multi-site trial is designed to evaluate the safety of administering rapidly-generated multi-antigen-specific T lymphocytes with the PD1 inhibitor Nivolumab, to relapsed/refractory (rel/ref) lymphoma patients with measurable disease (group A) or as adjunctive therapy following autologous HSCT (group B).

This study will first enroll 6 patients total (in Groups A and B) in the initial safety monitoring or DLT group prior to the expansion phase where additional 12 patients (6 in Group A and 6 in Group B) will be enrolled. TAA-T cells will be generated from patient's lymphocytes obtained from patient's PBMC.

If patient meets eligibility criteria for TAA-T cell infusion, the patient (Group A or Group B) will receive two TAA-T cell infusions given 2 weeks apart, where the expected volume of infusion is 1 to 10 cc.

Both TAA-T cells and Nivolumab will be given at the doses below with allowed de-escalation of both doses as follows:

  • TAA-T cell dose: 2 x 107 cells/m2 per infusion
  • Nivolumab: For patients <18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks

From the first 2 enrolled patients, if at least one patient meets dose limiting toxicity criteria (as described in section 6.4.1) at the above mentioned combination dose level, then the next 2 patients will receive TAA-T cells at 1 x 107 cells/m2 without a change in Nivolumab dose. If toxicity criteria are met by at least one patient from these 2 patients, then the dose of Nivolumab will be reduced to 1mg/kg/dose for patients <18 years or 100mg if receiving 240mg dosing or 200mg if receiving 480mg dosing for adult patients ≥18 years for next 2 patients and TAA-T cells will be given at the same de-escalated dose of 1x 107 cells/m2.

In case the patient experiences toxicity from Nivolumab prior to the first TAA-T cell infusion, they can receive the TAA-T cells after resolution of the Nivolumab toxicities and steroid dosing has been reduced less than 0.5mg/kg/day.

After the safety phase is complete, additional 12 patients total will be enrolled on expansion cohort.

Patients will receive doses Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.. Delays >3 days for the Nivolumab will not be considered protocol violations if discussed with the PI.

If the TAA-T cells are not ready after the initial doses of Nivolumab prior to the first TAA-T infusion, then the patients can continue Nivolumab infusions for an additional 8 weeks at the PI's discretion. If there is insufficient number of TAA-Ts for the two planned infusions, then additional blood may be drawn and patients can continue on Nivolumab unless they rapidly progress with disease requiring urgent therapy. If there is insufficient number of TAA-Ts to meet study dose, a lower dose of TAA-T may be infused at the discretion of the PI.

Only group A patients are eligible for additional doses ( 3 to 8) if they have stable disease or response, do not have ≥ grade 3 toxicity attributed to TAA-T cells and do not have clinical evidence of rapidly progressing disease requiring urgent therapy.

For Group B patients, blood for generation for TAA-T cells (non-mobilized) will be collected prior to the stem cell collection or any time after Day 30 post auto-HSCT. Treatment with Nivolumab will begin any time after Day 30 post auto-HSCT. Patients are eligible for Group B if they have no evidence of metabolically active disease by PET/CT (Deauville Score of 3 or less) at time of starting treatment with Nivolumab. Patients eligible for Group B with <CMR)/CR (by PET/CT) prior to auto-HSCT will need to be in CR (Deauville Score of 3 or less) prior to the start of Nivolumab or can be moved to Group A if they have metabolically active disease (Deauville Score of 4 or more) by PET/CT.

Patients should not receive other systemic antineoplastic agents including Nivolumab for at least 6 weeks after the first infusion of TAA-specific T-cells (for purposes of evaluation), although such treatment may be added if deemed critical for patient care by the attending physician.

Patients in Group A will not be able to receive additional doses (3-8) of TAA-T cells until the initial 6 weeks evaluation for toxicity and efficacy following the first TAA-T cell infusion.

Patients (Group A and B) will not receive subsequent doses of Nivolumab until the safety evaluation for TAA-T is over (at least 6 weeks from the first infusion).

Details
Condition Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Treatment Nivolumab, TAA-T cells
Clinical Study IdentifierNCT03843294
SponsorCatherine Bollard
Last Modified on7 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Group A (patients with measurable disease) Relapsed/Refractory Hodgkin Lymphoma (HL) and
Diffuse Large B cell Lymphoma (DLBCL) DLBCL
Patients who have failed at least 2 lines of prior therapy with a failed attempt at
both an autologous stem cell transplant and chimeric antigen receptor T cell therapy
Patients who are deemed autologous stem cell transplant ineligible and have failed
HL
only one line of prior therapy
Rel/ref after autologous HSCT
Systemic therapies to treat prior indolent lymphomas count towards previous DLBCL
lines of therapy unless the treatment was anti-CD20 antibody monotherapy
Rel/ref HL failing more than or equal to 1 salvage regimens, including prior
Patients with < CMR/CR (by PET/CT) with initial treatment regimen
Brentuximab Vedotin (BV)
Patients with <CMR/CR (by PET/CT) prior to autologous HSCT
Group B (consolidation after auto-HSCT for patients at high risk for relapse) DLBCL
Patients requiring >1 salvage regimen prior to autologous HSCT HL
Patients with relapse <12 months from diagnosis or <6 months from completion of
initial therapy
Patients with <CMR/CR (by PET/CT) prior to autologous HSCT
Patients requiring >1 salvage regimen prior to autologous HSCT
Patients with relapse <12 months from diagnosis or <6 months from completion of
Age >12 years
initial therapy
Karnofsky/Lansky score of more than or equal to 50 (see appendix C)
ALC > 600
Recipient Inclusion Criteria for Initial and Subsequent Procurements (TAA-T Cell
Generation)
Patient or parent/guardian capable of providing informed consent
Patients receiving Granulocyte colony-stimulating factor (G-CSF) are recommended a
Prior allogeneic BMT
washout period of a minimum of two weeks before procurement
Prior solid organ transplant
Agree to use contraceptive measures during study protocol participation (when age
appropriate)
Patient with uncontrolled infections
Patient with active HIV
Recipient Exclusion Criteria for Initial and Subsequent Procurements (TAA-T Cell
Pregnancy or lactating
Generation)
Failure to meet institutional guidelines for treatment with Nivolumab
Recipient Inclusion Criteria for Initial and Subsequent TAA-T Cell Infusions
Age >12 years
Patient who has received ATG, Campath or other immunosuppressive T cell monoclonal
Patient has received at least 8 weeks of Nivolumab
antibodies within 28 days of screening for enrollment
Steroids less than 0.5 mg/kg/day prednisone or equivalent
Karnofsky/Lansky score of more than or equal to 50
Pulse oximetry of > 90% on room air
Patient or parent/guardian capable of providing informed consent
Patients with Grade 1 toxicities attributed to Nivolumab will be eligible at the
discretion of the PI. Toxicities include but not limited to: laboratory abnormalities
in thyroid function tests suggestive of hypothyroidism, thyroiditis or thyroid
dysfunction adequately managed with thyroid hormone replacement, or abnormalities in
amylase, lipase
Bilirubin less than or equal to 2.5 mg/dL, AST/ALT less than or equal to 5x upper
limit of normal, serum creatinine < 1.0 or 2x the upper limit of normal (whichever is
higher)
Absolute neutrophil count > 250/µL (may be supported with GCSF)
Agree to use contraceptive measures during study protocol participation (when age
appropriate)

Exclusion Criteria

Investigational therapies within 28 days prior to screening for enrollment
Uncontrolled infections
Patient with ≥ grade 1 or symptomatic non-hematologic toxicities from prior therapies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note